Christopher Haqq - 02 Feb 2026 Form 4 Insider Report for Elicio Therapeutics, Inc. (ELTX)

Reporting relationship: Executive Vice President, Head of R&D and Chief Medical Officer
Issuer ticker: ELTX
Reported as of: 02 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Feb 2026, 16:33:56 UTC
Prior SEC filing: 04 Feb 2025
Next SEC filing: 17 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Christopher Haqq

Key filing fact

Christopher Haqq filed Form 4 for Elicio Therapeutics, Inc. (ELTX) on 03 Feb 2026.

Key facts

This page summarizes Christopher Haqq's Form 4 filing for Elicio Therapeutics, Inc. (ELTX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Feb 2026, 16:33.

Change

Previous filing in this sequence was filed on 04 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001612095 Primary reporting owner

Haqq Christopher

Relationship: Executive Vice President, Head of R&D and Chief Medical Officer
Address: C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON
Signature: /s/ Christopher Haqq
Signature date: 03 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ELTX transaction

Common Stock

Award

Transaction value: $0
Shares: +25,400
Change %: +79%
Price: $0.000000
Shares after: 57,381
Date: 02 Feb 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +50,900
Change %
Price: $0.000000
Shares after: 50,900
Date: 02 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,900
Exercise price: $8.10
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units ("RSUs") that will vest as to 25% of the RSUs on February 2, 2027, the first anniversary of the grant date, with the remaining RSUs vesting in annual installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Each RSU represents the right to receive one share of common stock, par value $0.01 per share, of the Issuer.

Footnote F2

The stock option vests and becomes exercisable as to 25% of the options on February 2, 2027, the first anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

SEC remarks

Executive Vice President, Head of R&D and Chief Medical Officer